Bibliography
- KELER T, GRAZIANO RF, MANDAL A et al.: Bispecific antibody-dependent cellular toxicity of Her 2/neu-over expressing tumor cells by Fc gamma receptor Type I-expressing effector cells. Cancer Res. (1997) 57:4008–4014.
- FERNANDEZSESMA A, SCHULMAN JL, MORAN TM: A bispecific antibody recognising influenza A virus M2 protein redirects effector cells to inhibit virus replica-tion in vitro. J. Virol (1996) 70:4800–4804.
- KONTERMANN RE, MARTINEAU P, CUMMINGS CE et al: Enzyme immunoassays using bispecific antibodies. Immunotechnology (1997) 3:137–144.
- TAZZARI PL, ZHANG S, CHEN Q et al.: Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin bispecific monoclonal antibody. Br. J. Cancer (1993) 67:1248–1253.
- BARBET J, PELTIER P, BARDET S et al.: Radioimmunode-tection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DPTA-indium bispecific antibody. J. Nucl. Med. (1998) 39:1172–1178.
- SHINMOTO H, KOBORI M, TSUSHIDA T, SHINOHARA K:Establishment of a mouse hybrid-hybridoma secreting bispecific antibodies to bovine lactoferrin and horseradish peroxidase. Biotechnol Letts. (1996) 10:661–666.
- BRENNAN M, DAVISON PF, PAULUS H: Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science (1985) 229:81–83.
- GLENNIE MJ, MCBRIDE HM, WORTH HT, STEVENSON GT: Preparation and performance of bispecific F(ab'-y)2 antibody containing thioether linked Fab'-y fragments. J. Immunol (1987) 139:2367–2375.
- SHALABY MR, SHEPARD HM, PRESTA L et al: Develop-ment of humanised bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overex-pressing the Her2 prot-oncogene. J. Exp. Med. (1992) 1:217–225.
- CARTER P, MERCHANT AM: Engineering antibodies for imaging and therapy. Curr. Opin. Biotechnol. (1997) 8:449–454.
- ••Excellent general review of recombinant antibody and itsfusions.
- PACK P, PLUCKTHUN A: New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology (1997) 3:83–105.
- ••Comprehensive review of multimeric antibodies andmultimeric binding.
- PACK P, PLUCKTHUN A: Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in Escherichia coli. Biochemistry (1992) 31:1579–1584.
- •Detailed research on the construction of bivalent scFvs and their function.
- KOSTELNY SA, COLE MS, TSO JY: Formation of a bispecific antibody by the use of leucine zippers. J. Immunol (1992) 148:1547–1553.
- MCGUINNESS BT, WALTER G, FITZGERALD K etal.: Phage diabody repertoires for the selection of large numbers of bispecific antibody fragments. Nature Biotechnol (1996) 14:1149–1154.
- •An extension of the diabody and phage display research to select for BsAbs.
- MULLER KM, ARNDT KM, STRITTMATTER W, PLUCKTHUN A: A dimeric bispecific miniantibody combines two specificities with avidity. FEBS Letts. (1998) 432:45–49.
- HU SZ, SHIVERY L, RAUBITSCHEK A et al.: Minibody: a novel engineered ant- carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high level targeting of xenografts. Cancer Res. (1996) 56:3055–3061.
- RIDGWAY JBB, PRESTA LG, CARER P: 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerisation. Prot. Engin. (1996) 9:617–621.
- ATWELL S, RIDGEWAY JBB, WELLS JA, CARTER P: Stable heterodimers from remodelling the domain interface of a homodimer using a phage display library. J. Mol. Biol. (1997) 270:26–35.
- •Nice use of semi-rational mutagenesis and selection to identify interacting domains.